GILEAD SCIENCES, INC.
Nasdaq: GILD·Foster City, California·CIK 0000882095
- Price
- $167.58
- Base IV
- $126.08
Valuation snapshot
At $167.58, the price sits between our base case ($126.08) and bull case ($209.09).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $126.08
- 75% of the price · range $67.11–$209.09
- Price vs base case
- 33% above
- $167.58 against $126.08
- Base case · our researched forecast, 2026-11-01See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $67.11 to bull $209.09. Values per share.
Price against each value
- Bear case
- $67.11
- Price 150% above
- No growth
- …
- —
- Base case
- $126.08
- Price 33% above
What does Gilead Sciences do?
Gilead makes medicines that treat and prevent HIV, treat viral hepatitis and COVID-19, and help patients fight cancers such as breast cancer and lymphoma, including with cell therapies.
It brought in $31B of sales in the 12 months to Sep 2026.
Led by Daniel O'Day, Chairman and Chief Executive Officer since 2019. Daniel O'Day
- Industry
- Healthcare
- Based in
- Foster City, California
- Trades on
- Nasdaq as GILD
Here is where each dollar a customer pays ends up. For every $1 of sales in the 12 months to Sep 2026, it spent about $1.12, so it lost 12¢ on each dollar. The biggest cost is everything else it takes to operate, 45¢ of every dollar.
- Making what it sells20¢
- Research and development20¢
- Sales, marketing and admin22¢
- Everything else it takes to operate45¢
- Interest and other costs1¢
- Tax4¢
- Lost on each dollar−12¢
Who pays Gilead Sciences, and for what?
Gilead Sciences develops medicines and sells them in more than 35 countries. Most of its money comes from HIV drugs, both to treat the infection and to prevent it. Biktarvy, a daily HIV pill, brought in about $14.3 billion of the company's roughly $29.4 billion in 2025 revenue. It also sells medicines for liver diseases and cancer, and earns a smaller amount from royalties and partnerships.
Gilead mostly sells to drug wholesalers: in the U.S., three of them (Cardinal Health, Cencora and McKesson) have historically handled about 90% of its gross product sales. Much of the final bill is paid by government programs like Medicare and Medicaid and by private insurers.
HIV
71%Medicines that treat or prevent HIV. They include Biktarvy, Descovy, Genvoya, Odefsey and Yeztugo, a twice-yearly shot that helps prevent infection.
Liver Disease
11%Treatments for hepatitis B and C and for a rare liver disease called primary biliary cholangitis. Products include Epclusa, Vemlidy and Livdelzi.
Epclusa tablet packagingImage: Shop Apotheke Cell Therapy
6%Yescarta and Tecartus. These cancer treatments take a patient's own immune cells and modify them to attack blood cancers.
Trodelvy
5%A cancer drug used mainly for certain types of breast cancer.
Veklury
3%An antiviral used to treat COVID-19 in hospitals. Its sales rise and fall with COVID waves.
Veklury injection vial packagingDoc James, CC BY-SA 4.0, via Wikimedia Commons Other products
3%Other medicines, such as AmBisome, which treats serious fungal infections.
Where its work physically happens, beyond headquarters:
- La Verne Manufacturing Facility — La Verne, United States. Manufactures AmBisome, packages and labels most commercial products for the Americas and Pacific Rim, and is being expanded for commercial sterile-drug production.
- Cork Manufacturing Facility — Cork, Ireland. Performs commercial manufacturing, packaging, labeling, quality-control testing, and final release for products distributed across the EU and other international markets.
- El Segundo Cell Therapy Facility — El Segundo, United States. Provides clinical and commercial manufacturing and processing capacity for Gilead's cell-therapy products.
- Frederick Cell Therapy Facility — Frederick, United States. Supports clinical and commercial manufacturing and processing of cell therapies within Gilead's capacity-constrained autologous manufacturing network.
- Oceanside Biologics Facility — Oceanside, United States. Manufactures clinical and commercial retroviral vectors and conducts process development for biologics candidates, supporting both cell-therapy supply and pipeline advancement.
How is the business doing?
Sales have barely moved over 9 years, from $30.4B in 2016 to $29.4B in 2025.
It spends more to run the business than it brings in: an operating loss of 8¢ per sales dollar.
After paying for its upkeep and new investment, it had $13.8B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Gilead says it exists to discover and deliver medicines for serious diseases such as HIV, liver disease and cancer, with the aim of making people around the world healthier.
“with the goal of creating a healthier world for all people”
Who is responsible for the plan?
- Daniel O'DayChairman and Chief Executive Officer
He oversees Gilead Sciences' overall corporate strategy, global business operations, and organizational management. Gilead generates revenue through the discovery, development, and global commercialization of biopharmaceutical therapies for life-threatening diseases.
- Johanna MercierChief Commercial & Corporate Affairs Officer
She oversees worldwide commercial operations, global product strategy, and corporate affairs across virology, oncology, and inflammation. Gilead's product revenues depend on the marketing, distribution, and commercial delivery of prescription medicines to healthcare providers and patients.
- Flavius MartinExecutive Vice President, Research
He oversees Gilead's internal discovery research, scientific strategy, and preclinical research programs across all therapeutic areas. Discovery research and preclinical programs generate the candidate molecules necessary to sustain Gilead's commercial product pipeline and future revenue.
Roles checked November 14, 2026.
What management says it is working on now:
Growing HIV prevention with Yeztugo
Management says Yeztugo, a twice-yearly shot that helps prevent HIV, has become the leading long-acting prevention option for people starting prevention. Sales of Gilead's HIV prevention products doubled from a year earlier and passed $1 billion in a single quarter for the first time.
Gilead Sciences Q2 2026 Earnings Prepared RemarksBuilding the next generation of HIV medicines
Gilead is developing HIV options that would be taken daily, weekly, monthly, twice a year or once a year. It is also seeking approval for a once-weekly Yeztugo pill. With Merck, it reported positive late-stage results for a once-weekly two-drug HIV pill.
Gilead Q2 2026 earnings press release (Form 8-K)Expanding in cancer through acquisitions
In 2026 Gilead bought Arcellx to own all of anito-cel, a cell therapy for multiple myeloma, a blood cancer. It also bought Tubulis, which develops targeted cancer drugs. These deals led to about $11.2 billion in one-time charges in the second quarter.
Gilead Sciences Q2 2026 Form 10-QUsing Trodelvy earlier in breast cancer
Trodelvy won U.S. and European approval in 2026 as a first treatment for advanced triple-negative breast cancer, a hard-to-treat type of breast cancer. It can be used alone or together with Merck's Keytruda. Trodelvy sales rose 26% in the second quarter.
Gilead Q2 2026 earnings press release (Form 8-K)Moving into immune and liver diseases
Gilead bought Ouro Medicines to gain a drug candidate for autoimmune diseases. It won the first U.S. approval of a treatment for hepatitis delta (Hepcludex). It also reported positive late-stage results that could widen the use of Livdelzi.
Gilead Q2 2026 earnings press release (Form 8-K)
- Total product sales, full year 2026
- $30.1 billion to $30.4 billion
- Gilead Q2 2026 earnings press release (Form 8-K)
- Product sales excluding Veklury, full year 2026
- $29.8 billion to $30.1 billion
- Gilead Q2 2026 earnings press release (Form 8-K)
- Product gross margin (non-GAAP), full year 2026
- About 87%
- Gilead Q2 2026 earnings press release (Form 8-K)
What's changing right now?
Growth is holding steady. In Q3 2026 it sold 7% more than a year earlier. The year before, quarters averaged 6%.
Its operating margin is narrower than a year ago: 42¢ per sales dollar, against 43¢.
Since Sep 2026 the share price has risen 11%, from $151.22 to $167.58.
Recently
August 4, 2026
Second-quarter Trodelvy sales changed to $457.0M
Gilead Q2 2026 resultsAugust 4, 2026
Second-quarter HIV product sales changed to $5.7B
Gilead Q2 2026 resultsFebruary 10, 2026
HIV product sales, full year changed to $20.8B
GILD Q4 FY25 Prepared Remarks
Coming up
Second half of 2026 (expected)
FDA decision on anito-cel
Gilead has asked the FDA to approve anito-cel, a cell therapy for multiple myeloma in patients who have already tried at least three earlier treatments. Gilead bought Arcellx in 2026 to own all of this drug. Management expects one potential cancer launch in the second half of 2026.
Gilead Q2 2026 earnings press release (Form 8-K)Second half of 2026 (expected)
Potential HIV launch in the second half of 2026
Besides the cancer launch, management expects one more potential launch in HIV in the second half of 2026. Its press release did not name the product.
Gilead Q2 2026 earnings press release (Form 8-K)Target decision date: February 2, 2027
FDA decision on a once-weekly Yeztugo pill
The FDA has accepted Gilead's request to approve a once-weekly pill version of Yeztugo to help prevent HIV.
Gilead Q2 2026 earnings press release (Form 8-K)2028
Biktarvy's negotiated Medicare price takes effect
The lower government-negotiated Medicare price for Biktarvy is scheduled to start, which could reduce revenue from the company's biggest product.
Gilead Sciences 2025 Form 10-K, Item 1A Risk Factors
Our own estimate moved too: the base case went from $97.65 to $126.08 a share between our last two valuations. The biggest reason: R&D expense ratio of total revenue moved from an unreported prior value to 20.5%, as reported in Gilead Sciences Form 10-K for Fiscal Year Ended December 31, 2024.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Medicare price negotiation for Biktarvy
In January 2026, the U.S. government chose Biktarvy, Gilead's biggest product, for Medicare price negotiation under the Inflation Reduction Act. The new price takes effect in 2028. Gilead expects negotiated prices to be substantially lower than current Medicare prices, and more of its drugs could be chosen later.
From the company's own filingsWould hit how fast sales growGilead Sciences 2025 Form 10-K, Item 1A Risk Factors
Heavy reliance on HIV
About 70% of 2025 revenue came from HIV medicines, and almost half from Biktarvy alone. If competitors, cheaper generic copies or new HIV drugs take away patients, Gilead says it might have to scale back its operations and research.
From the company's own filingsWould hit how fast sales growGilead Sciences 2025 Form 10-K, Item 1A Risk Factors
Patent expirations and generics
Sales usually fall sharply once cheaper copies can be sold. Key patents expire on different dates: Descovy in 2031 in the U.S. and 2027 in Europe, and Biktarvy in 2036 in the U.S. Legal challenges could open the door to copies earlier.
From the company's own filingsWould hit its growth in the long runGilead Sciences 2025 Form 10-K, Items 1 and 1A
Cell therapy sales declining
Sales of Yescarta and Tecartus fell 14% in the second quarter of 2026, which Gilead tied to competition, and it expects a mid-teens percentage decline for the year. These treatments are complex to make and rely on outside hospitals and clinics.
From the company's own filingsWould hit how fast sales growGilead Q2 2026 earnings press release (Form 8-K)
Drug trials can fail
Developing drugs is costly and uncertain. Several Trodelvy studies have missed their main goals, including EVOKE-01 in 2024 and ASCENT-07 in 2025, and the EVOKE-03 lung cancer study was stopped in 2026. Failures limit how much the expensive acquisitions pay off.
From the company's own filingsWould hit how much it has to reinvestGilead Sciences 2025 Form 10-K, Item 1A Risk Factors
Costly deals and more debt
The 2026 acquisitions led to a net loss of about $10.5 billion in the second quarter. By June 30, 2026, cash had fallen to about $3.2 billion from $7.6 billion at the end of 2025, and borrowing had risen, including $3.0 billion of new bonds and a $1.1 billion loan.
From the company's own filingsWould hit how much it has to reinvestGilead Sciences Q2 2026 Form 10-Q
Company-wide revenue growth slowed to 2.4% in 2025 from 6.0% in 2024 as Medicare Part D restructuring took effect.
From our researchWould hit how fast sales growGilead Sciences Historical Financial Summary
A heavy debt load
It owes $19.8B more than it holds in cash. The latest four quarters had no positive operating profit to compare with that debt.
From the numbers
Is it a good business?
From 2012 to 2025 it earned between 4% and 68% on the capital invested in it, a median of 20%. Its cost of capital in the latest valuation is 7.0%; returns were above it in 9 of the 10 years.
From 2012 to 2025 it earned between 2% and 98% on its shareholders' equity, a median of 29%.
Over 10 years its operating margin ranged from 6¢ to 68¢ per sales dollar, a median of 38¢. Gross margin ran from 71¢ to 86¢.
Cost of capital 7.0%
The number of shares has held roughly steady over the past year.
It owes $19.8B more than it holds in cash. The latest four quarters had no positive operating profit to compare with that debt.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $167.58. Our put its value between $67.11 and $209.09, with $126.08 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $67.11
This cautious scenario assumes that after sales grew to nearly thirty-one billion dollars, revenue flattens and gradually slips as older HIV treatments face government price cuts and tough competition, while new cancer drugs fail to make up the difference.
Base case, $126.08
This baseline scenario assumes Gilead maintains steady low-single-digit sales growth and solid profitability, as next-generation twice-yearly prevention medicines and expanding oncology sales offset declining pandemic antiviral demand and mandatory Medicare discounts.
Bull case, $209.09
This optimistic scenario assumes that Gilead's recent momentum accelerates, driven by rapid worldwide adoption of its twice-a-year HIV prevention injection and expanding cancer therapies, driving higher profits across the business.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 33%
For Gilead Sciences to be worth today's $167.58, sales would need to grow about 8.9% a year. We assume 3.0%. Over the last 5 years, sales grew 3.1% a year.
Or, if sales grow 3.0% as we assume, the price works with a profit margin of 48.5% (we assume 37.5%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 8.9% a year?
Try your own numbersWe're not very sure of this range: it scores 44 out of 100 on our checks. The weakest point is margin predictability.
Test the assumptions
Our base value of $126.08 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average3.0%
- Operating margin37.5%
- Long-term growth rate2.3%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$126.08 -24.8%


